Skip to main content
. 2023 Nov 9;30(2):450–461. doi: 10.1158/1078-0432.CCR-23-2313

Figure 2.

Figure 2. Sorafenib inhibits HIF1-mediated paracrine VEGF signaling. Effect of sorafenib on (A) the number of HUVEC tubes formed following co-culture with desmoid cells, (B) VEGFR2 phosphorylation in HUVEC cells treated with desmoid-conditioned media (+, desmoids grown in the presence of sorafenib; +*, sorafenib added to conditioned media after it was added to HUVEC cultures), (C) HIF1α expression and Akt phosphorylation, and (D) HIF1-mediated transcription as defined by a luciferase reporter assay (*, P < 0.05).

Sorafenib inhibits HIF1-mediated paracrine VEGF signaling. Effect of sorafenib on (A) the number of HUVEC tubes formed following co-culture with desmoid cells, (B) VEGFR2 phosphorylation in HUVEC cells treated with desmoid-conditioned media (+, desmoids grown in the presence of sorafenib; +*, sorafenib added to conditioned media after it was added to HUVEC cultures), (C) HIF1α expression and Akt phosphorylation, and (D) HIF1-mediated transcription as defined by a luciferase reporter assay (*, P < 0.05).